PreSize Diagnostic medical device software for increased precision in advance selection of best surgical scenario for every patient at point of diagnosis

PreSize 诊断医疗设备软件可提高精确度，在诊断时为每位患者提前选择最佳手术方案

• 批准号: 10073884
• 金额: $ 92.98万
• 依托单位: OXFORD HEARTBEAT LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10073884
• 关键词: PreSize; Diagnostic; medical; device; software

We have developed PreSize medical device software: a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside brain blood vessels with realistic, real-time simulations right before starting life-saving surgery. Using cutting-edge computational modelling, we make best use of patient imaging and device mechanics to accurately predict device behaviour inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing complications and cost of surgeries for hospitals/society.This project will extend/increase PreSize's power to support crucial clinical decision-making for more patients, across their journey from diagnosis to treatment. We will provide never-before-seen capabilities to clinicians and potential for aneurysm care pathways to be radically transformed. Specifically, we will advance the already ground-breaking PreSize to support diagnostic **CTA** scans(rapid, inexpensive, minimally-invasive imaging used for most patients suspected of aneurysm) in addition to (3D)**DSA** that PreSize currently uses(expensive, invasive imaging, but of significantly higher quality; used to guide placement of implant during procedure).**Proposed PreSize Diagnostic** adds Precision Medicine throughout the care pathway instead of only on surgery day, supporting patient-specific treatment stratification/planning and helping clinicians best prepare for surgery day (accommodating best implant choices and delivering best surgical outcomes) with unprecedented technological support. These technological advancements ultimately aim to reduce patient suffering, minimise healthcare costs, and optimise/standardise care.We are an award-winning start-up created to bring this novel technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by IUK and NIHR and receive ongoing support from The Royal Academy of Engineering. Our awards include:* NHS Innovation Award 2017* "Best Healthcare Start-up of 2018" (WIRED)* BioMedEng Innovation Prize 2021 for 'ground-breaking work which has led to new technologies that support medical interventions'* **IUK's 'Women in Innovation' Award 2023** for 'one of 50 of the UK's leading women entrepreneurs for game-changing ideas'We were selected for the DigitalHealth.London Accelerator programme, and were one of 6 startups selected globally by Philips Healthcare Accelerator. We have featured in the general press, e.g., Forbes, WIRED, The Times, Financial Times, The Telegraph, etc. Most recently, PreSize was captured in action in the **BBC Click** tech show (February 3, 2023, BBC iPlayer).We aim to grow Oxford Heartbeat to become the leading provider of clinical decision-support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.

我们开发了PreSize医疗器械软件：一种新颖的临床决策支持解决方案，可帮助外科医生在开始挽救生命的手术之前，通过逼真的实时模拟来规划和排练脑血管内的植入物放置。使用尖端的计算建模，我们充分利用患者成像和器械力学来准确预测每个患者血管解剖结构内的器械行为。这使得临床医生能够为每位患者选择最佳设备，从而减少医院/社会的并发症和手术成本。该项目将扩展/增加PreSize的能力，为更多患者从诊断到治疗的整个过程中提供关键的临床决策支持。我们将为临床医生提供前所未有的能力，并有可能从根本上改变动脉瘤护理途径。具体来说，我们将推进已经突破性的PreSize，以支持诊断性 **CTA** 扫描（快速、廉价、微创成像，用于大多数疑似动脉瘤的患者），以及PreSize目前使用的（3D）**DSA**（昂贵、侵入性成像，但质量明显更高;用于在手术过程中指导植入物的放置）。拟议的PreSize诊断 ** 在整个护理路径中增加了精准医疗，而不仅仅是在手术当天，支持患者特定的治疗分层/计划，并帮助临床医生在前所未有的技术支持下为手术日做好最好的准备（适应最佳植入物选择并提供最佳手术结果）。这些技术进步的最终目标是减少患者痛苦，最大限度地降低医疗成本，并优化/简化护理。我们是一家屡获殊荣的初创企业，旨在将这项新技术引入医院。凭借强大的工程，软件，商业，法律的和监管专家团队，我们以前一直得到IUK和NIHR的支持，并得到皇家工程学院的持续支持。我们的奖项包括：* 2017年NHS创新奖 *“2018年最佳医疗保健初创企业”（WIRED）* 2021年BioMedEng创新奖，表彰“开创性工作，带来了支持医疗干预的新技术”* 2023年IUK“女性创新”奖 **，表彰“英国50位领先的女性企业家之一，提出了改变游戏规则的想法”我们入选了DigitalHealth.伦敦加速器计划，是飞利浦医疗保健加速器全球选出的6家初创企业之一。我们在一般媒体上有特色，例如，福布斯，有线，泰晤士报，金融时报，电讯报等最近，PreSize被抓获的行动在 **BBC点击 ** 科技节目（2023年2月3日，BBC iPlayer）。我们的目标是将牛津心跳发展成为临床决策支持工具的领先提供商，促进英国经济及其在医疗保健领域的国际领导地位，改善全民医疗保健，并定义未来的医学